New drug combo aims to wipe out kidney cancer before surgery

NCT ID NCT04322955

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving two drugs—nivolumab (immunotherapy) and cabozantinib (targeted therapy)—before removing the kidney can make all visible cancer disappear in people with advanced kidney cancer that has spread. About 38 adults with metastatic renal cell carcinoma will receive the drugs for 12 weeks, then have surgery. The goal is to see if this approach leads to a complete response, meaning no cancer remains detectable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44012, United States

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Ohio State University Wexner Medical Center

    Columbus, Ohio, 43221, United States

  • The Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States